早期支架内血栓的危险因素分析及相关预防措施评价
|
摘要
背景药物洗脱支架(DES)明显降低支架内再狭窄和靶病变再次血运重建率,但是支架内血栓仍然是潜在危险。其发生率很低但预后很差。预防支架内血栓仍是目前冠心病介入领域的研究热点和难点。
目的通过分析DES早期支架内血栓(EST)发生的危险因素,评价光学相干断层成像(OCT)对改善DES置入质量的指导作用,观察经皮冠状动脉介入治疗(PCI)围术期补液速度与血小板聚集率(RPA)的关系,从而探讨优化介入质量和围术期管理对预防EST的作用。
方法1、回顾分析2004年至2008年连续行PCI治疗的冠心病患者的临床及介入资料,建立Excel数据库,查找EST的主要可控危险因素。2、分析2007年至2009年连续行OCT检查及支架置入患者的PCI及OCT资料,分析不同压力下内膜脱垂、夹层及支架贴壁质量。3、设计前瞻性随机对照试验,评价围术期不同补液速度对DES置入后RPA的影响。
结果
(一)EST的危险因素分析
1、570例连续完成PCI治疗的冠心病患者中有4例(0.70%)在DES置入后平均4.25天发生EST。
2、发生EST患者的主要危险因素有：高龄、吸烟、多种原因支架贴壁不良及围术期管理不当等；其中主要可控危险因素包括支架贴壁不良和围术期管理不当。
3、EST患者的临床表现主要为持续性胸痛和低血压状态,部分合并心源性休克(25%)、上消化道出血(50%)和顽固性心室颤动(25%),虽经急诊介入、药物及其它治疗,但病死率仍高达50%。
(二)OCT对DES贴壁质量的观察及后扩张的指导作用
1、OCT检查过程中有7例(22.6%)患者发生一过性心绞痛和轻微ST段改变,无恶性心律失常、急性血栓等严重心血管事件发生。
2、支架贴壁距离：厚壁支架Cypher和EXCEL之间无统计学差异(140.19±18.08μm比138.98±12.15μm,P>0.05)；薄壁支架Partner和TAXUS之间无统计学差异(124.43±10.50μm比121.08±11.64μm,P>0.05)；厚壁支架Cypher和EXCEL与薄壁支架Partner和TAXUS相比均有统计学差异(P<0.05)
3、与命名压扩张相比,4种不同支架在后扩张的支架贴壁距离更近(P<0.05),内膜脱垂和支架边缘微小夹层发生率更低(P<0.05)
(三)围术期补液速度对DES置入后RPA的影响
1、与常规补液相比,快速补液并不增加出血、心力衰竭等并发症的发生(P>0.05)。
2、两组患者的血压、心率、血清渗透压等指标均无统计学差异(P>0.05),但快速补液组术后4小时的RPA较常规补液组明显降低(P<0.05)。
3、常规补液组有3例患者在PCI术后发生心绞痛等临床症状,怀疑容量不足致EST,急诊造影检查除外支架内血栓且经快速补液等治疗后临床症状消失。
结论
1、EST的主要可控危险因素是支架置入质量和围术期管理。
2、支架贴壁距离与支架的总厚度有关。
3、后扩张明显减少支架贴壁不良,降低内膜脱垂和支架边缘微小夹层的发生率。
4、PCI围术期快速补液能够降低RPA,有利于预防EST。
5、优化介入质量和围术期管理有可能是降低EST的有效措施。
Background Drug-eluting stents (DES) have significantly reduced the restenosis and target lesion revascularization rate, but stent thrombosis (ST) is still a potential danger for patients. Preventing the incidence of ST is still a hot and difficult spot in the coronary intervention.
Objective (1) To analyze the main risk factors of early stent thrombosis (EST). (2) To evaluate the guidance of OCT in the optimization of DES implantation. (3) To observe the relationship between fluid infusion speed and RPA during perioperative of PCI. (4) To investigate the effective of optimizing the quality of intervention and perioperative management to prevent EST.
Methods (1) A cohort of consecutive patients treated with PCI from 2004 to 2008 were retrospectively analysized. Their clinical and intervention data were recorded and an Excel database was established to analysis the major controllable risk factors of EST. (2) The PCI and OCT data of the patients who have finished OCT examinations and stent implantion from 2007 to 2009 were studied, and the optimization of DES adherence, intimal prolapse degree and dissection were analysized. (3) A prospective and randomized controlled trial was designed to evaluate the effect of different fluid infusion speed on RPA.
Results
(1) Four patients (0.70%) in 570 patients with coronary heart disease treated with PCI had EST during an average of 4.25 days after DES implantion.
(2) Main risk factors of EST include aging, smoking heavy, stent malapposition and perioperative mismanagement.
(3) Persistent chest pain and low BP occured in patients with EST. Some had cardiogenic shock (25%) and refractory ventricular fibrillation (25%). Even through treated with emergency treatments,50% mortality were still existed.
(4) During OCT examination, only 7 patients had transient angina and mild ST segment changes. There were no serious cardiovascular events.
(5) There was no significant difference with stent adherent distance between Cypher and EXCEL stent, as well as Partner and TAXUS stent (P >0.05). There was significant difference between Cyphe/EXCEL group with Partner/TAXUS group (P<0.05).
(6) The distance between the vessel wall and stent after post-dilatation was significantly shorter than that of the named stent expansion in kinds of stents (P <0.05). The incidence of intimal prolapse and dissection after post-dilatation were significantly less than that of named stent expansion (P<0.05).
(7) Compared with the conventional infusion, rapid infusion did not increase bleeding, heart failure and other complications (P> 0.05).
(8) RPA in rapid infusion group was significantly lower than that of conventional infusion group after four hours (P<0.05).
(9) There were 3 patients who had angina after PCI in the conventional fluid group. EST was suspected because of insufficient body fluid capacity. Emergency angiography excluded thrombus, but symptoms disappeared after rapid infusion.
Conclusions
(1) Optimization of DES implantation and perioperative management are major controllable risk factors of EST.
(2) The distance of stent adherence depends on the total thickness of stents.
(3) Post-dilatation can reduce stent malapposition, depress the incidence of intimal prolapse and dissection.
(4) Rapid fluid influsion can reduce perioperativ RPA, and profiting to prevent EST.
(5) Optimizing stent implantion and perioperative management could be effective measures to reduce EST.
目的通过分析DES早期支架内血栓(EST)发生的危险因素,评价光学相干断层成像(OCT)对改善DES置入质量的指导作用,观察经皮冠状动脉介入治疗(PCI)围术期补液速度与血小板聚集率(RPA)的关系,从而探讨优化介入质量和围术期管理对预防EST的作用。
方法1、回顾分析2004年至2008年连续行PCI治疗的冠心病患者的临床及介入资料,建立Excel数据库,查找EST的主要可控危险因素。2、分析2007年至2009年连续行OCT检查及支架置入患者的PCI及OCT资料,分析不同压力下内膜脱垂、夹层及支架贴壁质量。3、设计前瞻性随机对照试验,评价围术期不同补液速度对DES置入后RPA的影响。
结果
(一)EST的危险因素分析
1、570例连续完成PCI治疗的冠心病患者中有4例(0.70%)在DES置入后平均4.25天发生EST。
2、发生EST患者的主要危险因素有：高龄、吸烟、多种原因支架贴壁不良及围术期管理不当等；其中主要可控危险因素包括支架贴壁不良和围术期管理不当。
3、EST患者的临床表现主要为持续性胸痛和低血压状态,部分合并心源性休克(25%)、上消化道出血(50%)和顽固性心室颤动(25%),虽经急诊介入、药物及其它治疗,但病死率仍高达50%。
(二)OCT对DES贴壁质量的观察及后扩张的指导作用
1、OCT检查过程中有7例(22.6%)患者发生一过性心绞痛和轻微ST段改变,无恶性心律失常、急性血栓等严重心血管事件发生。
2、支架贴壁距离：厚壁支架Cypher和EXCEL之间无统计学差异(140.19±18.08μm比138.98±12.15μm,P>0.05)；薄壁支架Partner和TAXUS之间无统计学差异(124.43±10.50μm比121.08±11.64μm,P>0.05)；厚壁支架Cypher和EXCEL与薄壁支架Partner和TAXUS相比均有统计学差异(P<0.05)
3、与命名压扩张相比,4种不同支架在后扩张的支架贴壁距离更近(P<0.05),内膜脱垂和支架边缘微小夹层发生率更低(P<0.05)
(三)围术期补液速度对DES置入后RPA的影响
1、与常规补液相比,快速补液并不增加出血、心力衰竭等并发症的发生(P>0.05)。
2、两组患者的血压、心率、血清渗透压等指标均无统计学差异(P>0.05),但快速补液组术后4小时的RPA较常规补液组明显降低(P<0.05)。
3、常规补液组有3例患者在PCI术后发生心绞痛等临床症状,怀疑容量不足致EST,急诊造影检查除外支架内血栓且经快速补液等治疗后临床症状消失。
结论
1、EST的主要可控危险因素是支架置入质量和围术期管理。
2、支架贴壁距离与支架的总厚度有关。
3、后扩张明显减少支架贴壁不良,降低内膜脱垂和支架边缘微小夹层的发生率。
4、PCI围术期快速补液能够降低RPA,有利于预防EST。
5、优化介入质量和围术期管理有可能是降低EST的有效措施。
Background Drug-eluting stents (DES) have significantly reduced the restenosis and target lesion revascularization rate, but stent thrombosis (ST) is still a potential danger for patients. Preventing the incidence of ST is still a hot and difficult spot in the coronary intervention.
Objective (1) To analyze the main risk factors of early stent thrombosis (EST). (2) To evaluate the guidance of OCT in the optimization of DES implantation. (3) To observe the relationship between fluid infusion speed and RPA during perioperative of PCI. (4) To investigate the effective of optimizing the quality of intervention and perioperative management to prevent EST.
Methods (1) A cohort of consecutive patients treated with PCI from 2004 to 2008 were retrospectively analysized. Their clinical and intervention data were recorded and an Excel database was established to analysis the major controllable risk factors of EST. (2) The PCI and OCT data of the patients who have finished OCT examinations and stent implantion from 2007 to 2009 were studied, and the optimization of DES adherence, intimal prolapse degree and dissection were analysized. (3) A prospective and randomized controlled trial was designed to evaluate the effect of different fluid infusion speed on RPA.
Results
(1) Four patients (0.70%) in 570 patients with coronary heart disease treated with PCI had EST during an average of 4.25 days after DES implantion.
(2) Main risk factors of EST include aging, smoking heavy, stent malapposition and perioperative mismanagement.
(3) Persistent chest pain and low BP occured in patients with EST. Some had cardiogenic shock (25%) and refractory ventricular fibrillation (25%). Even through treated with emergency treatments,50% mortality were still existed.
(4) During OCT examination, only 7 patients had transient angina and mild ST segment changes. There were no serious cardiovascular events.
(5) There was no significant difference with stent adherent distance between Cypher and EXCEL stent, as well as Partner and TAXUS stent (P >0.05). There was significant difference between Cyphe/EXCEL group with Partner/TAXUS group (P<0.05).
(6) The distance between the vessel wall and stent after post-dilatation was significantly shorter than that of the named stent expansion in kinds of stents (P <0.05). The incidence of intimal prolapse and dissection after post-dilatation were significantly less than that of named stent expansion (P<0.05).
(7) Compared with the conventional infusion, rapid infusion did not increase bleeding, heart failure and other complications (P> 0.05).
(8) RPA in rapid infusion group was significantly lower than that of conventional infusion group after four hours (P<0.05).
(9) There were 3 patients who had angina after PCI in the conventional fluid group. EST was suspected because of insufficient body fluid capacity. Emergency angiography excluded thrombus, but symptoms disappeared after rapid infusion.
Conclusions
(1) Optimization of DES implantation and perioperative management are major controllable risk factors of EST.
(2) The distance of stent adherence depends on the total thickness of stents.
(3) Post-dilatation can reduce stent malapposition, depress the incidence of intimal prolapse and dissection.
(4) Rapid fluid influsion can reduce perioperativ RPA, and profiting to prevent EST.
(5) Optimizing stent implantion and perioperative management could be effective measures to reduce EST.
引文
[1]. Mueller RL, Sanborn TA. The history of interventional cardiology:cardiac catheterization, angioplasty, and related interventions. Am Heart J.1995, 129(1):146-172
[2]. Danchin N, Juilliere Y, Kettani C, et al. Effect on early acute occlusion rate of adjunctive antithrombotic treatment with intravenously administered dipyridamole during percutaneous transluminal coronary angioplasty. Am Heart J.1994,127(3):494-498
[3].Narins CR, Holmes DR Jr, Topol EJ. A call for provisional stenting:the balloon is back! Circulation.1998,97(13):1298-1305
[4]. Serruys PW, Umans V, Heyndrickx GR, et al. Elective PTCA of totally occluded coronary arteries not associated with acute myocardial infarction; short-term and long-term results. Eur Heart J.1985,6(1):2-12
[5]. Cowley MJ, Dorros G, Kelsey SF, et al. Acute coronary events associated with percutaneous transluminal coronary angioplasty. Am J Cardiol.1984,53(12): 12C-16C
[6]. O'Neill WW, Weintraub R, Grines CL, et al. A prospective, placebo-controlled, randomized trial of intravenous streptokinase and angioplasty versus lone angioplasty therapy of acute myocardial infarction. Circulation.1992,86(6): 1710-1717
[7]. Hirshfeld JW Jr, Schwartz JS, Jugo R, et al. Restenosis after coronary angioplasty:a multivariate statistical model to relate lesion and procedure variables to restenosis. The M-Heart Investigators. J Am Coll Cardiol.1991, 18(3):647-56
[8]. King SB III. The development of interventional cardiology. J Am Coll Cardiol. 1998,31(4 suppl B):64B-88B
[9]. Schatz RA, Palmaz JC, Tio FO, et al. Balloon-expandable intracoronary stents in the adult dog. Circulation.1987,76(2):450-457
[10].Sigwart U, Puel J, Mirkovitch V, et al. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med.1987, 316(12):701-706
[11].Roubin GS, Cannon AD, Agrawal SK, et al. Intracoronary stenting for acute and threatened closure complicating percutaneous transluminal coronary angioplasty. Circulation.1992,85(3):916-927
[12].Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent study group. N Engl J Med.1994, 331(8):489-495
[13].Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med.1994, 331(8):496-501
[14].Agostoni P, Kedhi E, Verheye S, et al. Dissimilar relevance given to diseases by medical literature, and the potential to create biases in the clinical decision-making process:the case of late stent thrombosis. Int J Cardiol.2007, 114(2):E38-E39
[15].Saia F, Lemos PA, Lee CH, et al. Sirolimus-eluting stent implantation in ST-elevation acute myocardial infarction:a clinical and angiographic study. Circulation.2003,108(16):1927-1929
[16]. Colombo A, Drzewiecki J, Banning A, et al. Randomized study to assess the effectiveness of slow-and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation.2003,108(7):788-794
[17]. Granada JF, Kaluza GL, Raizner A. Drug-eluting stents for cardiovascular disorders. Curr Atheroscler Rep.2003,5(4):308-316
[18]. Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol.2006,48(1): 193-202
[19].Finn AV, Joner M, Nakazawa G, et al. Pathological correlates of late drug-eluting stent thrombosis:strut coverage as a marker of endothelialization. Circulation.2007,115(18):2435-2341
[20].Joner M, Nakazawa G, Finn AV, et al. Endothelial cell recovery between comparator polymer-based drug-eluting stents. J Am Coll Cardiol.2008,52(5): 333-342
[21].Park DW, Park SW, Park KH, et al. Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up. Am J Cardiol.2006,98(3):352-356
[22].Kaul S, Shah PK, Diamond GA. As time goes by:current status and future directions in the controversy over stenting. J Am Coll Cardiol.2007,50(2): 128-137
[23].Pfisterer M, Brunner-La Rocca HP, et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents:an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol.2006,48(12):2584-2591
[24].Tamura A, Watanabe T, Nagase K, et al. Circadian variation in symptomatic subacute stent thrombosis after bare metal coronary stent implantation. Am J Cardiol.2006,97(2):195-197
[25]. Thomas F, Jan S, Franz R, et al. Drug-eluting stent and coronary thrombosis biological mechaniams and clinical implications. Circulations.2007,115(8): 1051-1058
[26].Lord SJ, Howard K, Allen F, et al. A systematic review and economic analysis of drug-eluting coronary stents available in Australia. Med J Aust. 2005,183(9):464-471
[27].Waksman R. Biodegradable stents:they do their job and disappear. J invasive Cardiol.2006,18(2):70-74
[28].周圣华,卢才义,张玉霄,等。老年急性冠脉综合征患者药物洗脱支架内亚急性血栓原因分析。中华老年多器官疾病杂志,2009,8(1)：51-54
[29].周圣华,卢才义,张玉霄,等。替罗非班对复杂冠脉病变置入药物洗脱 支架后亚急性血栓的影响。中华老年多器官疾病杂志,2009,8(6)：517-520
[30].de Jaegere P, Mudra H, Figulla H, et al. Intravascular ultrasound-guided optimized stent deployment. Immediate and 6 months clinical and angiographic results from the Multicenter Ultrasound Stenting in Coronaries Study (MUSIC Study). Eur Heart J.1998,19(8):1214-1223
[31].Colombo A, Hall P, Nakamura S, et al. Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. Circulation.1995,91(6):1676-1688
[32].Romagnoli E, Sangiorgi GM, Cosgrave J, et al. Drug eluting stenting:the case for post-dilation. J Am Coll Cardiol Intv.2008,1:22-31
[33].Cheneau E, Leborgne L, Mintz GS, et al. Predictors of subacute stent thrombosis:results of a systematic intravascular ultrasound study. Circulation. 2003,108 (1):43-47
[34].周圣华,卢才义,颜伟,等。高压后扩张对药物洗脱支架置入后支架内亚急性血栓的影响。生物医学工程与临床。2010,14(1)：42-44
[35].周圣华,卢才义,张玉霄,等。光学相干断层成像对冠状动脉支架置入后高压球囊后扩张的指导作用。临床荟萃,2010,25(5)：383-385
[36].Vaknin-Assa H, Assali A, Ukabi S, et al. Stent thrombosis following drug-eluting stent implantation. A single-center experience. Cardiovasc Revasc Med.2007,8(4):243-247
[37].Ong AT, Hoye A, Aoki J, et al. Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation. J Am Coll Cardiol.2005,45(6):947-953
[38].陈纪林,杨跃进,黄静涵,等。冠心病真实世界中药物洗脱支架置入术后血栓形成的发生率。中华心血管病杂志,2007,35(12)：1133-1135
[39].王慧峰,邬冬梅,王凤群,等。冠状动脉支架内血栓形成原因分析。中西医结合心脑血管病杂志,2007,5(7)：628-629
[40].冠状动脉支架置入术后亚急性血栓形成3例。临床心血管病杂志,2006,22(9)： 566-567
[41].张立新,张海滨,张正海,等。国产药物洗脱支架在急诊冠脉介入治疗中导致急性支架内血栓形成的临床分析。中国心血管病研究杂志,2008,6(5)：358-360
[42].颜红兵,刘景山,张坚,等。直接冠状动脉介入治疗支架内血栓形成的发生率、危险因素及预后。中国介入心脏病学杂志,2004,12(3)：135-138
[43].韩雅玲,梁明,荆全民,等。52例冠状动脉支架内血栓形成患者的临床特点及介入治疗。中华心心血管病杂志,2006,34(11)：975-978
[44].谌彦,欧柏青,杨玉莲。冠状动脉介入术后支架内血栓形成(附6例报告)。中国医师杂志,2007,9(6)：778-779
[45].Wykrzykowska JJ, Raber L, de Vries T, et al. Biolimus-eluting biodegradable polymer versus sirolimus-eluting permanent polymer stent performance in long lesions:results from the LEADERS multicentre trial substudy. EuroIntervention.2009,5(3):310-317
[46].宋现涛,陈韵岱,吕树铮,等。复杂冠状动脉病变西罗莫司洗脱支架置入后急性和亚急性支架内血栓形成情况分析。中国介入心脏病学杂志,2006,14(3)：131-134
[47].Mosseri M, Miller H, Tamari I, et al. The Titanium-NO Stent:results of a multicenter registry. EuroIntervention.2006,2(2):192-196
[48]. de Man FH, Stella PR, Nathoe H, et al. Stent thrombosis in real-world patients:a comparison of drug-eluting with bare metal stents. Neth Heart J. 2007,5(11):382-386
[49].Kuchulakanti PK, Chu WW, Torguson R, et al. Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus and paclitaxel-eluting stents. Circulation.2006,113(8):1108-1113
[50].Orford JL, Lennon R, Melby S, et al. Frequency and correlates of coronary stent thrombosis in the modern era:analysis of a single center registry. J Am Coll Cardiol.2002,40(9):1567-1572
[51].Lemos PA, Lee CH, Degertekin M, et al. Early outcome after sirolimus-eluting stent implantation in patients with acute coronary syndromes:
insights from the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. J Am Coll Cardiol.2003,41(11): 2093-2099
[52].Farb A, Burke AP, Kolodgie FD, et al. Pathological mechanisms of fatal late coronary stent thrombosis in humans. Circulation.2003,108(14):1701-1706
[53].Pinto Slottow TL, Waksman R. Overview of the 2006 Food and Drug Administration Circulatory System Devices Panel meeting on drug-eluting stent thrombosis. Catheter Cardiovasc Interv.2007,69(7):1064-1074
[54].Cheneau E, Leborgne L, Mintz GS, et al. Predictors of subacute stent thrombosis:results of a systematic intravascular ultrasound study. Circulation. 2003,108(1):43-47
[55].Moussa I, Oetgen M, Roubin G, et al. Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation. Circulation.1999,99(18):2364-2366
[56].Regar E, van Leeuwen TG, Serruys PW. Optical coherence tomography in cardiovascular research. United Kingdom.2007.1st.3-53
[57].Gonzalo N, Serruys PW, Okamura T, et al. Optical coherence tomography assessment of the acute effects of stent implantation on the vessel wall:a systematic quantitative approach. Heart.2009,95(23):1913-1919
[58]. Jung IK, Tearney G, Bouma B. Visualization of tissue prolapse between coronary stent struts by optical coherence tomography:comparison with intravascular ultrasound. Circulation.2001,104(22):2754
[59].Terashima M, Rathore S, Suzuki Y, et al. Accuracy and reproducibility of stent-strut thickness determined by optical coherence tomography. J Invasive Cardiol.2009,21(11):602-605
[60].Tanigawa J, Barlis P, Dimopoulos K, et al. The influence of strut thickness and cell design on immediate apposition of drug-eluting stents assessed by optical coherence tomography. Int J Cardiol.2009,134(2):,180-188
[61].Yabushita H, Bouma BE, Houser SL, et al. Characterization of human atherosclerosis by optical coherence tomography. Circulation.2002,106 (13): 1640-1645
[62].Jang IK, Bouma BE, Kang DH, et al. Visualization of coronary atherosclerotic plaques in patients using optical coherence tomography: comparison with intravascular ultrasound. J Am Coll Cardiol.2002,39(4): 604-609
[63].Bouma BE, Tearney GJ, Yabushita H, et al. Evaluation of intracoronary stenting by intravascular optical coherence tomography. Heart.2003,89(3): 317-320
[64].Diaz-Sandoval LJ, Bouma BE, Tearney GJ, et al. Optical coherence tomography as a tool for percutaneous coronary interventions. Catheter Cardiovasc Interv.2005,65(4):492-496
[65].Ramcharitar S, Gonzalo N, van Geuns RJ, et al. First case of stenting of a vulnerable plaque in the SECRITT I trial-the dawn of a new era? Nat Rev Cardiol.2009,6(5):374-378
[66].Tanigawa J, Barlis P, Dimopoulos K, et al. Optical coherence tomography to assess malapposition in overlapping drug-eluting stents. EuroIntervention. 2008,3(5):580-583
[67].Tian F, Chen YD, Sun ZJ, et al. Evaluation of the late stent malapposition after drug-eluting stent implantation by optical coherence tomography. Zhonghua Xin Xue Guan Bing Za Zhi.2009,37(7):585-589
[68].Bezerra HG, Costa MA, Guagliumi G, et al. Intracoronary optical coherence tomography:a comprehensive review clinical and research applications. JACC Cardiovasc Interv.2009,2(11):1035-1046
[69]. Barlis P, Regar E, Serruys PW, et al. An optical coherence tomography study of a biodegradable vs. durable polymer-coated limus-eluting stent:a LEADERS trial sub-study. Eur Heart J.2010,31(2):165-176
[70].Kubo T, Imanishi T, Kitabata H, et al. Comparison of vascular response after sirolimus-eluting stent implantation between patients with unstable and stable angina pectoris:a serial optical coherence tomography study. JACC Cardiovasc Imaging.2008,1(4):475-484
[71].Jakabcin J, Spacek R, Bystron M, et al. Long-term health outcome and mortality evaluation after invasive coronary treatment using drug eluting stents with or without the IVUS guidance. Randomized control trial. HOME DES IVUS. Catheter Cardiovasc Interv.2010,75(4):578-583
[72].Rathore S, Terashima M, Suzuki T. Late-acquired stent malapposition after sirolimus-eluting stent implantation following acute coronary syndrome: angiographic, IVUS, OCT and coronary angioscopic observation. J Invasive Cardiol.2009,21(12):666-667
[73].Sawada T, Shite J, Shinke T, et al. Very late thrombosis of sirolimus-eluting stent due to late malapposition:Serial observations with optical coherence tomography. J Cardiol.2008,52(3):290-295
[74].Chen BX, Ma FY, Luo W, et al. Neointimal coverage of bare-metal and sirolimus-eluting stents evaluated with optical coherence tomography. Heart. 2008,94(5):566-570
[75].Takano M, Inami S, Jang IK, et al. Evaluation by optical coherence tomography of neointimal coverage of sirolimus-eluting stent three months after implantation. Am J Cardiol.2007,99(8):1033-1038
[76].Matsumoto D, Shite J, Shinke T, et al. Neointimal coverage of sirolimus-eluting stents at 6-month follow-up:evaluated by optical coherence tomography. Eur Heart J.2007,28(8):961-967
[77].Roy P, Steinberg DH, Sushinsky SJ, et al. The potential clinical utility of intravascular ultrasound guidance in patients undergoing percutaneous coronary intervention with drug-eluting stents. Eur Heart J.2008,29(15): 1851-1857
[78].陈玉国,张运,徐峰,等。血管内超声指导急性冠脉综合征患者药物洗脱支架置入的研究。中华超声影像学杂志,2006,15(6)：401-404
[79].Serruys PW, van Der Giessen W, Garcia E, et al. Clinical and Angiographic Results with the Multi-Link Stent Implanted under Intravascular Ultrasound Guidance (West-2 Study). J Invasive Cardiol.1998,10 (Suppl B):20B-27B
[80].Murata A, Wallace-Bradley D, Tellez A, et al. Accuracy of optical coherence tomography in the evaluation of neointimal coverage after stent implantation. JACC Cardiovasc Imaging.2010,3(1):76-84
[81].Sawada T, Shite J, Negi N, et al. Factors that influence measurements and accurate evaluation of stent apposition by optical coherence tomography. Assessment using a phantom model. Circ J.2009,73(10):1841-1847
[82].Tanigawa J, Barlis P, Di Mario C. Intravascular optical coherence tomography: optimisation of image acquisition and quantitative assessment of stent strut apposition. EuroIntervention.2007,3(1):128-136
[83].Cimalla P, Walther J, Mehner M, et al. Simultaneous dual-band optical coherence tomography in the spectral domain for high resolution in vivo imaging. Opt Express.2009,17(22):19486-19500
[84].Hou JB, Meng LB, Jing SH, et al. Combined use of optical coherence tomography and intravascular ultrasound during percutaneous coronary intervention in patients with coronary artery disease. Zhonghua Xin Xue Guan Bing Za Zhi.2008,36(11):980-984
[85]. Jang IK, Tearney G, Bouma B. Visualization of tissue prolapse between coronary stent struts by optical coherence tomography:comparison with intravascular ultrasound. Circulation.2001,104(22):2754
[86].Diaz-Sandoval LJ, Bouma BE, Tearney GJ, et al. Optical coherence tomography as a tool for percutaneous coronary interventions. Catheter Cardiovasc Interv.2005,65(4):492-496
[87].Fujimoto JG, Boppart SA, Tearney GJ, et al. High resolution in vivo intra-arterial imaging with optical coherence tomography. Heart.1999,82(2): 128-133
[88].Gerckens U, Buellesfeld L, McNamara E, et al. Optical Coherence Tomography (OCT). Potential of a new high-resolution intracoronary imaging
technique. Herz.2003,28(6):496-500
[89].颜伟,卢才义,张玉霄,等。光学相干断层成像在老年冠心病介入诊疗中的初步应用。中华老年多器官疾病杂志。2007,6(2)：97-102
[90].Tearney GJ, Waxman S, Shishkov M, et al. Three-dimensional coronary artery microscopy by intracoronary optical frequency domain imaging. JACC Cardiovasc Imaging.2008,1(6):752-761
[91].Chen FK, Patel PJ, Coffey PJ, et al. Increased fundus autofluorescence in neovascular age-related macular degeneration is associated with outer segment shortening in macular translocation model. Invest Ophthalmol Vis Sci.2010, (Epub ahead of print)
[92].Tearney GJ, Waxman S, Shishkov M, et al. Three-dimensional coronary artery microscopy by intracoronary optical frequency domain imaging. JACC Cardiovasc Imaging.2008,1(6):752-761
[93].Takarada S, Imanishi T, Liu Y, et al. Advantage of next-generation frequency-domain optical coherence tomography compared with conventional time-domain system in the assessment of coronary lesion. Catheter Cardiovasc Interv.2010,75(2):202-206
[94].Rao AK, Pratt C, Berke A, et al. Thrombolysis in Myocardial Infarction (TIMI) Trial--phase I:hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol.1988,11(1): 1-11
[95].Born GV. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature.1962,194:927-929
[96].赵明,蒋鹏,谷俊侠,等。羟乙基淀粉对血液流变学的影响。陕西医学杂志。2004,33(1)：9-11
[97].李亚茹,史婧,李娟利。冠状动脉介入治疗术后低血压与补液。实用心脑肺血管病杂志.2007,15(5)：380-381
[98].黄岚,覃军。经皮介入诊疗血管径路并发症的防治。海南医学。2002, 13(12)： 127-138
[99].Fejka M, Dixon SR, Safian RD, et al. Diagnosis, management, and clinical outcome of cardiac tamponade complicating percutaneous coronary intervention. Am J Cardiol.2002,90(11):1183-1186
[100]. Farouque HM, Tremmel JA, Raissi Shabari F, et al. Risk factors for the development of retroperitoneal hematoma after percutaneous coronary intervention in the era of glycoprotein Ⅱb/Ⅲa inhibitors and vascular closure devices. J Am Coll Cardiol.2005,45(3):363-368
[101]. Movahed MR, Balian H, Moraghebi P. Reversible severe ischemic mitral regurgitation and cardiogenic shock as a complication of percutaneous coronary intervention. J Invasive Cardiol.2005,17(2):104-107
[102]. Movahed MR, Butman SM. The pathogenesis and treatment of no-reflow occurring during percutaneous coronary intervention. Cardiovasc Revasc Med. 2008,9(1):56-61
[103]. Banfic L, Vrkic Kirhmajer M, Vojkovic M, et al. Access site complications following cardiac catheterization assessed by duplex ultrasonography. Coll Antropol.2008,32(2):385-390
[104]. Nikolsky E, Mehran R, Turcot D, et al. Impact of chronic kidney disease on prognosis of patients with diabetes mellitus treated with percutaneous coronary intervention. Am J Cardiol.2004,94(3):300-305
[105]. Valente S, Lazzeri C, Giglioli C, et al. Contrast-induced nephropathy in urgent coronary interventions. J Cardiovasc Med (Hagerstown).2006, 7(10):737-741
[1]. Mueller RL, Sanborn TA. The history of interventional cardiology:cardiac catheterization, angioplasty, and related interventions. Am Heart J.1995, 129(1):146-172
[2]. Danchin N, Juilliere Y, Kettani C, et al. Effect on early acute occlusion rate of adjunctive antithrombotic treatment with intravenously administered dipyridamole during percutaneous transluminal coronary angioplasty. Am Heart J.1994,127(3):494-498
[3].Narins CR, Holmes DR Jr, Topol EJ. A call for provisional stenting:the balloon is back! Circulation,1998,97(13):1298-1305
[4]. Serruys PW, Umans V, Heyndrickx GR, et al.403.Elective PTCA of totally occluded coronary arteries not associated with acute myocardial infarction; short-term and long-term results. Eur Heart J.1985,6(1):2-12
[5]. Cowley MJ, Dorros G, Kelsey SF, et al. Acute coronary events associated with percutaneous transluminal coronary angioplasty. Am J Cardiol.1984, 53(12):12C-16C
[6]. O'Neill WW, Weintraub R, Grines CL, et al. A prospective, placebo-controlled, randomized trial of intravenous streptokinase and angioplasty versus lone angioplasty therapy of acute myocardial infarction. Circulation.1992,86(6):1710-1717
[7]. Hirshfeld JW Jr, Schwartz JS, Jugo R, et al. Restenosis after coronary angioplasty:a multivariate statistical model to relate lesion and procedure variables to restenosis. The M-Heart Investigators. J Am Coll Cardiol.1991, 18(3):647-56
[8]. King SB III. The development of interventional cardiology. J Am Coll Cardiol.1998,31(4 suppl B):64B-88B
[9].Schatz RA, Palmaz JC, Tio FO, et al. Balloon-expandable intracoronary stents in the adult dog. Circulation.1987,76(2):450-457
[10].Sigwart U, Puel J, Mirkovitch V, et al. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med.1987, 316(12):701-706
[11].Roubin GS, Cannon AD, Agrawal SK, et al. Intracoronary stenting for acute and threatened closure complicating percutaneous transluminal coronary angioplasty. Circulation.1992,85(3):916-927
[12].Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent study group. N Engl J Med.1994, 331(8):489-495
[13].Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med. 1994,331(8):496-501
[14].Saia F, Lemos PA, Lee CH, et al. Sirolimus-eluting stent implantation in ST-elevation acute myocardial infarction:a clinical and angiographic study. Circulation.2003,108(16):1927-1929
[15].Colombo A, Drzewiecki J, Banning A, et al. Randomized study to assess the effectiveness of slow-and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation.2003,108(7):788-794
[16]. Granada JF, Kaluza GL, Raizner A. Drug-eluting stents for cardiovascular disorders. Curr Atheroscler Rep.2003,5(4):308-316
[17].Kerner A, Gruberg L, Kapeliovich M, et al. Late stent thrombosis after implantation of a sirolimus-eluting stent. Catheter Cardiovasc Interv.2003, 60(4):505-508
[18].Tsimikas S. Drug-eluting stents and late adverse clinical outcomes lessons learned, lessons awaited. J Am Coll Cardiol.2006,47(10):2112-2115
[19].Rodriguez AE, Mieres J, Fernandez-Pereira C, et al. Coronary stent thrombosis in the current drug-eluting stent era:insights from the ERACI III trial. J Am Coll Cardiol.2006,47(1):205-207
[20].Tamura A, Watanabe T, Nagase K, et al. Circadian variation in symptomatic subacute stent thrombosis after bare metal coronary stent implantation. Am J Cardiol.2006,97(2):195-197
[21]. Colombo A, Hall P, Nakamura S, et al. Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. Circulation.1995,91(6):1676-1688
[22]. Stone GW, Moses JW, Ellis SG, et al. Safety and efficacy of sirolimus-and paclitaxel-eluting coronary stents. N Engl J Med.2007,356(10):998-1008.
[23].Lau WC, Neer CJ, Watkins PB, et al. Clopidogrel nonresponders discovered during point-of-care platelet aggregation testing. J Am Coll Cardiol.2003, 41(Suppl):225A-226A
[24].McFadden EP, Stabile E, Regar E, et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet.2004, 364(94444):1519-1521
[25].Karvouni E, Korovesis S, Katritsis DG. Very late thrombosis after implantation of sirolimus eluting stent. Heart.2005,91(6):e45
[26]. Finn AV, Joner M, Nakazawa G, et al. Pathological correlates of late drug-eluting stent thrombosis:strut coverage as a marker of endothelialization. Circulation.2007,115(18):2435-2441
[27].Kotani J, Awata M, Nanto S, et al. Incomplete neointimal coverage of sirolimus-eluting stents:angioscopic findings. J Am Coll Cardiol.2006, 47(10):2108-2111
[28]. Win HK, Caldera AE, Maresh K, et al. Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. JAMA.2007, 297(18):2001-2009
[29].Fleisher LA, Beckman JA, Brown KA, et al. ACC/AHA 2007 Guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: Executive summary:A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation.2007,116(17):1971-1796
[30].Pfisterer M, Brunner-La Rocca HP, Buser PT, et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents:An observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol.2006,48(12):2584-2591
[31].Camenzind E, Steg PG, Wijns W. Stent thrombosis late after implantation of first-generation drug-eluting stents:a cause for concern. Circulation.2007, 115(11):1440-1455
[32].Daemen J, Ong AT, Stefanini GG, et al. Three-year clinical follow-up of the unrestricted use of Sirolimus-eluting stents as part of the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) Registry. Am J Cardiol.2006,98(7):895-901
[33].Williams DO, Abbott JD, Kip KE, et al. Outcomes of 6906 patients undergoing percutaneous coronary intervention in the era of drug-eluting stents:report of the DEScover Registry. Circulation.2006,114(20): 2154-2162
[34].Grines CL, Bonow RO, Casey DE Jr, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents:a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association,with representation from the American College of Physicians. Circulation.2007,115(6):813-818
[35].Ong AT, Hoye A, Aoki J, et al. Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent imp lantation. J Am Coll Cardiol.2005,45(6):947-953
[36].Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA.2005,293(17):2126-2130
[1]. Jang IK, Tearney G, Bouma B. Visualization of tissue prolapse between coronary stent struts by optical coherence tomography:comparison with intravascular ultrasound. Circulation.2001,104 (22):2754
[2]. Yabushita H, Bouma BE, Houser SL, et al. Characterization of human atherosclerosis by optical coherence tomography. Circulation.2002,106 (13): 1640-1645
[3]. Tearney GJ, Yabushita H, Houser SL, et al. Quantification of macrophage content in atherosclerotic plaques by optical coherence tomography. Circulation.2003,107:113-119
[4]. Suzuki Y, Ikeno F, Koizumi T, et al. In vivo comparison between optical coherence tomography and intravascular ultrasound for detecting small degrees of in-stent neointima after stent implantation. JACC Cardiovasc Interv.2008,1(2):168-173
[5]. Tearney GJ, Jang IK, Kang DH, et al. Porcine coronary imaging in vivo by optical coherence tomography. Acta Cardiol.2000,55(4):233-237
[6].Zimarino M, Prati F, Stabile E, et al. Optical coherence tomography accurately identifies intermediate atherosclerotic lesions--an in vivo evaluation in the rabbit carotid artery. Atherosclerosis.2007,193(1):94-101
[7]. Patwari P, Weissman NJ, Boppart SA, et al. Assessment of coronary plaque with optical coherence tomography and high-frequency ultrasound. Am J Cardiol.2000,85(5):641-644
[8]. Garcia-Garcia HM, Gonzalo N, Granada JF, et al. Diagnosis and treatment of coronary vulnerable plaques. Expert Rev Cardiovasc Ther.2008,6(2): 209-222
[9].Naghavi M, Libby P, Falk E, et al. From vulnerable plaque to vulnerable patient:a call for new definitions and risk assessment strategies:Part Ⅱ. Circulation.2003,108(15):1772-1778
[10].Tearney GJ, Yabushita H, Houser SL, et al. Quantification of macrophage content in atherosclerotic plaques by optical coherence tomography. Circulation.2003,107(1):113-119
[11].Gerckens U, Buellesfeld L, McNamara E, et al. Optical Coherence Tomography (OCT). Potential of a new high-resolution intracoronary imaging technique. Herz.2003,28(6):496-500
[12].Diaz-Sandoval LJ, Bouma BE, Tearney GJ, et al. Optical coherence tomography as a tool for percutaneous coronary interventions. Catheter Cardiovasc Interv.2005,65(4):492-496
[13].Bouma BE, Tearney GJ, Yabushita H, et al. Evaluation of intracoronary stenting by intravascular optical coherence tomography. Heart.2003,89(3): 317-320
[14].曹华明,蒋金法,邓兵,等。心肌桥的光学相干断层成像诊断及临床意义。中国介入心脏病学杂志,2009,17(6)：324-326
[15].de Jaegere P, Mudra H, Figulla H, et al. Intravascular ultrasound-guided optimized stent deployment. Immediate and 6 months clinical and angiographic results from the Multicenter Ultrasound Stenting in Coronaries Study (MUSIC Study). Eur Heart J.1998,19(8):1214-1223
[16].Colombo A, Hall P, Nakamura S, et al. Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. Circulation.1995,91(6):1676-1688
[17].Romagnoli E, Sangiorgi GM, Cosgrave J, et al. Drug eluting stenting:the case for post-dilation. J Am Coll Cardiol Intv.2008,1:22-31
[18].周圣华,卢才义,张玉霄,等。光学相干断层成像对冠状动脉支架置入后高压球囊后扩张的指导作用。临床荟萃,2010,25(5)：383-385
[19].Bouma BE, Tearney GJ, Yabushita H, et al. Evaluation of intracoronary stenting by intravascular optical coherence tomography. Heart.2003,89 (3): 317-320
[20].Ito S, Itoh M, Suzuki T. Intracoronary imaging with optical coherence tomography after cutting balloon angioplasty for in-stent restenosis. J Invasive Cardiol.2005,17(7):369-370
[21].Karantalis V, Davlouros P, Alexopoulos D. Intimal hyperplasia by optical coherence tomography after BMS and DES implantation in the same artery. Int J Cardiol.2009, (article in press)
[22].陈步星、马凤云、罗维等。光学相干断层成像评价药物洗脱支架与金属裸支架治疗后的内膜增值。中华医学杂志,2006,86(16)：1102-1106
[23].Ormiston JA, Serruys PW, Regar E, et al. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB):a prospective open-label trial. Lancet. 2008,371 (9616):899-907
[24]. Serruys PW, Ormiston JA, Onuma Y, et al. A bioabsorbable everolimus-eluting coronary stent system (ABSORB):2-year outcomes and results from multiple imaging methods. Lancet.2009,373(9667):869-870
[25].Fujii K, Masutani M, Ohyanagi M. Contribution of organized thrombus to in-stent restenosis after sirolimus-eluting stent implantation:optical coherence tomography findings. Eur Heart J.2008,29(11):1385
[26].Takano M, Xie Y, Murakami D, et al. Various optical coherence tomographic findings in restenotic lesions after sirolimus-eluting stent implantation. Int J Cardiol.2009,15,134(2):263-265
[27].Fujimoto JG, Boppart SA, Tearney GJ, et al. High resolution in vivo intra-arterial imaging with optical coherence tomography. Heart.1999,82: 128-133
[28].Gerckens U, Buellesfeld L, McNamara E, et al. Optical Coherence Tomography (OCT). Potential of a new high-resolution intracoronary imaging technique. Herz.2003,28(6):496-500
[29].颜伟,卢才义,张玉霄,等。光学相干断层成像在冠状动脉临界病变诊疗中的作用。中国介入心脏病学杂志。2007,15(3)：170
[30].Tearney GJ, Waxman S, Shishkov M, et al. Three-dimensional coronary artery microscopy by intracoronary optical frequency domain imaging. JACC Cardiovasc Imaging.2008,1(6):752-761
[31].Tearney GJ, Waxman S, Shishkov M, et al. Three-dimensional coronary artery microscopy by intracoronary optical frequency domain imaging. JACC Cardiovasc Imaging.2008,1(6):752-761
[32].Takarada S, Imanishi T, Liu Y, et al. Advantage of next-generation frequency-domain optical coherence tomography compared with conventional time-domain system in the assessment of coronary lesion. Catheter Cardiovasc Interv.2010,75(2):202-206
[2]. Danchin N, Juilliere Y, Kettani C, et al. Effect on early acute occlusion rate of adjunctive antithrombotic treatment with intravenously administered dipyridamole during percutaneous transluminal coronary angioplasty. Am Heart J.1994,127(3):494-498
[3].Narins CR, Holmes DR Jr, Topol EJ. A call for provisional stenting:the balloon is back! Circulation.1998,97(13):1298-1305
[4]. Serruys PW, Umans V, Heyndrickx GR, et al. Elective PTCA of totally occluded coronary arteries not associated with acute myocardial infarction; short-term and long-term results. Eur Heart J.1985,6(1):2-12
[5]. Cowley MJ, Dorros G, Kelsey SF, et al. Acute coronary events associated with percutaneous transluminal coronary angioplasty. Am J Cardiol.1984,53(12): 12C-16C
[6]. O'Neill WW, Weintraub R, Grines CL, et al. A prospective, placebo-controlled, randomized trial of intravenous streptokinase and angioplasty versus lone angioplasty therapy of acute myocardial infarction. Circulation.1992,86(6): 1710-1717
[7]. Hirshfeld JW Jr, Schwartz JS, Jugo R, et al. Restenosis after coronary angioplasty:a multivariate statistical model to relate lesion and procedure variables to restenosis. The M-Heart Investigators. J Am Coll Cardiol.1991, 18(3):647-56
[8]. King SB III. The development of interventional cardiology. J Am Coll Cardiol. 1998,31(4 suppl B):64B-88B
[9]. Schatz RA, Palmaz JC, Tio FO, et al. Balloon-expandable intracoronary stents in the adult dog. Circulation.1987,76(2):450-457
[10].Sigwart U, Puel J, Mirkovitch V, et al. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med.1987, 316(12):701-706
[11].Roubin GS, Cannon AD, Agrawal SK, et al. Intracoronary stenting for acute and threatened closure complicating percutaneous transluminal coronary angioplasty. Circulation.1992,85(3):916-927
[12].Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent study group. N Engl J Med.1994, 331(8):489-495
[13].Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med.1994, 331(8):496-501
[14].Agostoni P, Kedhi E, Verheye S, et al. Dissimilar relevance given to diseases by medical literature, and the potential to create biases in the clinical decision-making process:the case of late stent thrombosis. Int J Cardiol.2007, 114(2):E38-E39
[15].Saia F, Lemos PA, Lee CH, et al. Sirolimus-eluting stent implantation in ST-elevation acute myocardial infarction:a clinical and angiographic study. Circulation.2003,108(16):1927-1929
[16]. Colombo A, Drzewiecki J, Banning A, et al. Randomized study to assess the effectiveness of slow-and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation.2003,108(7):788-794
[17]. Granada JF, Kaluza GL, Raizner A. Drug-eluting stents for cardiovascular disorders. Curr Atheroscler Rep.2003,5(4):308-316
[18]. Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol.2006,48(1): 193-202
[19].Finn AV, Joner M, Nakazawa G, et al. Pathological correlates of late drug-eluting stent thrombosis:strut coverage as a marker of endothelialization. Circulation.2007,115(18):2435-2341
[20].Joner M, Nakazawa G, Finn AV, et al. Endothelial cell recovery between comparator polymer-based drug-eluting stents. J Am Coll Cardiol.2008,52(5): 333-342
[21].Park DW, Park SW, Park KH, et al. Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up. Am J Cardiol.2006,98(3):352-356
[22].Kaul S, Shah PK, Diamond GA. As time goes by:current status and future directions in the controversy over stenting. J Am Coll Cardiol.2007,50(2): 128-137
[23].Pfisterer M, Brunner-La Rocca HP, et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents:an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol.2006,48(12):2584-2591
[24].Tamura A, Watanabe T, Nagase K, et al. Circadian variation in symptomatic subacute stent thrombosis after bare metal coronary stent implantation. Am J Cardiol.2006,97(2):195-197
[25]. Thomas F, Jan S, Franz R, et al. Drug-eluting stent and coronary thrombosis biological mechaniams and clinical implications. Circulations.2007,115(8): 1051-1058
[26].Lord SJ, Howard K, Allen F, et al. A systematic review and economic analysis of drug-eluting coronary stents available in Australia. Med J Aust. 2005,183(9):464-471
[27].Waksman R. Biodegradable stents:they do their job and disappear. J invasive Cardiol.2006,18(2):70-74
[28].周圣华,卢才义,张玉霄,等。老年急性冠脉综合征患者药物洗脱支架内亚急性血栓原因分析。中华老年多器官疾病杂志,2009,8(1)：51-54
[29].周圣华,卢才义,张玉霄,等。替罗非班对复杂冠脉病变置入药物洗脱 支架后亚急性血栓的影响。中华老年多器官疾病杂志,2009,8(6)：517-520
[30].de Jaegere P, Mudra H, Figulla H, et al. Intravascular ultrasound-guided optimized stent deployment. Immediate and 6 months clinical and angiographic results from the Multicenter Ultrasound Stenting in Coronaries Study (MUSIC Study). Eur Heart J.1998,19(8):1214-1223
[31].Colombo A, Hall P, Nakamura S, et al. Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. Circulation.1995,91(6):1676-1688
[32].Romagnoli E, Sangiorgi GM, Cosgrave J, et al. Drug eluting stenting:the case for post-dilation. J Am Coll Cardiol Intv.2008,1:22-31
[33].Cheneau E, Leborgne L, Mintz GS, et al. Predictors of subacute stent thrombosis:results of a systematic intravascular ultrasound study. Circulation. 2003,108 (1):43-47
[34].周圣华,卢才义,颜伟,等。高压后扩张对药物洗脱支架置入后支架内亚急性血栓的影响。生物医学工程与临床。2010,14(1)：42-44
[35].周圣华,卢才义,张玉霄,等。光学相干断层成像对冠状动脉支架置入后高压球囊后扩张的指导作用。临床荟萃,2010,25(5)：383-385
[36].Vaknin-Assa H, Assali A, Ukabi S, et al. Stent thrombosis following drug-eluting stent implantation. A single-center experience. Cardiovasc Revasc Med.2007,8(4):243-247
[37].Ong AT, Hoye A, Aoki J, et al. Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation. J Am Coll Cardiol.2005,45(6):947-953
[38].陈纪林,杨跃进,黄静涵,等。冠心病真实世界中药物洗脱支架置入术后血栓形成的发生率。中华心血管病杂志,2007,35(12)：1133-1135
[39].王慧峰,邬冬梅,王凤群,等。冠状动脉支架内血栓形成原因分析。中西医结合心脑血管病杂志,2007,5(7)：628-629
[40].冠状动脉支架置入术后亚急性血栓形成3例。临床心血管病杂志,2006,22(9)： 566-567
[41].张立新,张海滨,张正海,等。国产药物洗脱支架在急诊冠脉介入治疗中导致急性支架内血栓形成的临床分析。中国心血管病研究杂志,2008,6(5)：358-360
[42].颜红兵,刘景山,张坚,等。直接冠状动脉介入治疗支架内血栓形成的发生率、危险因素及预后。中国介入心脏病学杂志,2004,12(3)：135-138
[43].韩雅玲,梁明,荆全民,等。52例冠状动脉支架内血栓形成患者的临床特点及介入治疗。中华心心血管病杂志,2006,34(11)：975-978
[44].谌彦,欧柏青,杨玉莲。冠状动脉介入术后支架内血栓形成(附6例报告)。中国医师杂志,2007,9(6)：778-779
[45].Wykrzykowska JJ, Raber L, de Vries T, et al. Biolimus-eluting biodegradable polymer versus sirolimus-eluting permanent polymer stent performance in long lesions:results from the LEADERS multicentre trial substudy. EuroIntervention.2009,5(3):310-317
[46].宋现涛,陈韵岱,吕树铮,等。复杂冠状动脉病变西罗莫司洗脱支架置入后急性和亚急性支架内血栓形成情况分析。中国介入心脏病学杂志,2006,14(3)：131-134
[47].Mosseri M, Miller H, Tamari I, et al. The Titanium-NO Stent:results of a multicenter registry. EuroIntervention.2006,2(2):192-196
[48]. de Man FH, Stella PR, Nathoe H, et al. Stent thrombosis in real-world patients:a comparison of drug-eluting with bare metal stents. Neth Heart J. 2007,5(11):382-386
[49].Kuchulakanti PK, Chu WW, Torguson R, et al. Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus and paclitaxel-eluting stents. Circulation.2006,113(8):1108-1113
[50].Orford JL, Lennon R, Melby S, et al. Frequency and correlates of coronary stent thrombosis in the modern era:analysis of a single center registry. J Am Coll Cardiol.2002,40(9):1567-1572
[51].Lemos PA, Lee CH, Degertekin M, et al. Early outcome after sirolimus-eluting stent implantation in patients with acute coronary syndromes:
insights from the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. J Am Coll Cardiol.2003,41(11): 2093-2099
[52].Farb A, Burke AP, Kolodgie FD, et al. Pathological mechanisms of fatal late coronary stent thrombosis in humans. Circulation.2003,108(14):1701-1706
[53].Pinto Slottow TL, Waksman R. Overview of the 2006 Food and Drug Administration Circulatory System Devices Panel meeting on drug-eluting stent thrombosis. Catheter Cardiovasc Interv.2007,69(7):1064-1074
[54].Cheneau E, Leborgne L, Mintz GS, et al. Predictors of subacute stent thrombosis:results of a systematic intravascular ultrasound study. Circulation. 2003,108(1):43-47
[55].Moussa I, Oetgen M, Roubin G, et al. Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation. Circulation.1999,99(18):2364-2366
[56].Regar E, van Leeuwen TG, Serruys PW. Optical coherence tomography in cardiovascular research. United Kingdom.2007.1st.3-53
[57].Gonzalo N, Serruys PW, Okamura T, et al. Optical coherence tomography assessment of the acute effects of stent implantation on the vessel wall:a systematic quantitative approach. Heart.2009,95(23):1913-1919
[58]. Jung IK, Tearney G, Bouma B. Visualization of tissue prolapse between coronary stent struts by optical coherence tomography:comparison with intravascular ultrasound. Circulation.2001,104(22):2754
[59].Terashima M, Rathore S, Suzuki Y, et al. Accuracy and reproducibility of stent-strut thickness determined by optical coherence tomography. J Invasive Cardiol.2009,21(11):602-605
[60].Tanigawa J, Barlis P, Dimopoulos K, et al. The influence of strut thickness and cell design on immediate apposition of drug-eluting stents assessed by optical coherence tomography. Int J Cardiol.2009,134(2):,180-188
[61].Yabushita H, Bouma BE, Houser SL, et al. Characterization of human atherosclerosis by optical coherence tomography. Circulation.2002,106 (13): 1640-1645
[62].Jang IK, Bouma BE, Kang DH, et al. Visualization of coronary atherosclerotic plaques in patients using optical coherence tomography: comparison with intravascular ultrasound. J Am Coll Cardiol.2002,39(4): 604-609
[63].Bouma BE, Tearney GJ, Yabushita H, et al. Evaluation of intracoronary stenting by intravascular optical coherence tomography. Heart.2003,89(3): 317-320
[64].Diaz-Sandoval LJ, Bouma BE, Tearney GJ, et al. Optical coherence tomography as a tool for percutaneous coronary interventions. Catheter Cardiovasc Interv.2005,65(4):492-496
[65].Ramcharitar S, Gonzalo N, van Geuns RJ, et al. First case of stenting of a vulnerable plaque in the SECRITT I trial-the dawn of a new era? Nat Rev Cardiol.2009,6(5):374-378
[66].Tanigawa J, Barlis P, Dimopoulos K, et al. Optical coherence tomography to assess malapposition in overlapping drug-eluting stents. EuroIntervention. 2008,3(5):580-583
[67].Tian F, Chen YD, Sun ZJ, et al. Evaluation of the late stent malapposition after drug-eluting stent implantation by optical coherence tomography. Zhonghua Xin Xue Guan Bing Za Zhi.2009,37(7):585-589
[68].Bezerra HG, Costa MA, Guagliumi G, et al. Intracoronary optical coherence tomography:a comprehensive review clinical and research applications. JACC Cardiovasc Interv.2009,2(11):1035-1046
[69]. Barlis P, Regar E, Serruys PW, et al. An optical coherence tomography study of a biodegradable vs. durable polymer-coated limus-eluting stent:a LEADERS trial sub-study. Eur Heart J.2010,31(2):165-176
[70].Kubo T, Imanishi T, Kitabata H, et al. Comparison of vascular response after sirolimus-eluting stent implantation between patients with unstable and stable angina pectoris:a serial optical coherence tomography study. JACC Cardiovasc Imaging.2008,1(4):475-484
[71].Jakabcin J, Spacek R, Bystron M, et al. Long-term health outcome and mortality evaluation after invasive coronary treatment using drug eluting stents with or without the IVUS guidance. Randomized control trial. HOME DES IVUS. Catheter Cardiovasc Interv.2010,75(4):578-583
[72].Rathore S, Terashima M, Suzuki T. Late-acquired stent malapposition after sirolimus-eluting stent implantation following acute coronary syndrome: angiographic, IVUS, OCT and coronary angioscopic observation. J Invasive Cardiol.2009,21(12):666-667
[73].Sawada T, Shite J, Shinke T, et al. Very late thrombosis of sirolimus-eluting stent due to late malapposition:Serial observations with optical coherence tomography. J Cardiol.2008,52(3):290-295
[74].Chen BX, Ma FY, Luo W, et al. Neointimal coverage of bare-metal and sirolimus-eluting stents evaluated with optical coherence tomography. Heart. 2008,94(5):566-570
[75].Takano M, Inami S, Jang IK, et al. Evaluation by optical coherence tomography of neointimal coverage of sirolimus-eluting stent three months after implantation. Am J Cardiol.2007,99(8):1033-1038
[76].Matsumoto D, Shite J, Shinke T, et al. Neointimal coverage of sirolimus-eluting stents at 6-month follow-up:evaluated by optical coherence tomography. Eur Heart J.2007,28(8):961-967
[77].Roy P, Steinberg DH, Sushinsky SJ, et al. The potential clinical utility of intravascular ultrasound guidance in patients undergoing percutaneous coronary intervention with drug-eluting stents. Eur Heart J.2008,29(15): 1851-1857
[78].陈玉国,张运,徐峰,等。血管内超声指导急性冠脉综合征患者药物洗脱支架置入的研究。中华超声影像学杂志,2006,15(6)：401-404
[79].Serruys PW, van Der Giessen W, Garcia E, et al. Clinical and Angiographic Results with the Multi-Link Stent Implanted under Intravascular Ultrasound Guidance (West-2 Study). J Invasive Cardiol.1998,10 (Suppl B):20B-27B
[80].Murata A, Wallace-Bradley D, Tellez A, et al. Accuracy of optical coherence tomography in the evaluation of neointimal coverage after stent implantation. JACC Cardiovasc Imaging.2010,3(1):76-84
[81].Sawada T, Shite J, Negi N, et al. Factors that influence measurements and accurate evaluation of stent apposition by optical coherence tomography. Assessment using a phantom model. Circ J.2009,73(10):1841-1847
[82].Tanigawa J, Barlis P, Di Mario C. Intravascular optical coherence tomography: optimisation of image acquisition and quantitative assessment of stent strut apposition. EuroIntervention.2007,3(1):128-136
[83].Cimalla P, Walther J, Mehner M, et al. Simultaneous dual-band optical coherence tomography in the spectral domain for high resolution in vivo imaging. Opt Express.2009,17(22):19486-19500
[84].Hou JB, Meng LB, Jing SH, et al. Combined use of optical coherence tomography and intravascular ultrasound during percutaneous coronary intervention in patients with coronary artery disease. Zhonghua Xin Xue Guan Bing Za Zhi.2008,36(11):980-984
[85]. Jang IK, Tearney G, Bouma B. Visualization of tissue prolapse between coronary stent struts by optical coherence tomography:comparison with intravascular ultrasound. Circulation.2001,104(22):2754
[86].Diaz-Sandoval LJ, Bouma BE, Tearney GJ, et al. Optical coherence tomography as a tool for percutaneous coronary interventions. Catheter Cardiovasc Interv.2005,65(4):492-496
[87].Fujimoto JG, Boppart SA, Tearney GJ, et al. High resolution in vivo intra-arterial imaging with optical coherence tomography. Heart.1999,82(2): 128-133
[88].Gerckens U, Buellesfeld L, McNamara E, et al. Optical Coherence Tomography (OCT). Potential of a new high-resolution intracoronary imaging
technique. Herz.2003,28(6):496-500
[89].颜伟,卢才义,张玉霄,等。光学相干断层成像在老年冠心病介入诊疗中的初步应用。中华老年多器官疾病杂志。2007,6(2)：97-102
[90].Tearney GJ, Waxman S, Shishkov M, et al. Three-dimensional coronary artery microscopy by intracoronary optical frequency domain imaging. JACC Cardiovasc Imaging.2008,1(6):752-761
[91].Chen FK, Patel PJ, Coffey PJ, et al. Increased fundus autofluorescence in neovascular age-related macular degeneration is associated with outer segment shortening in macular translocation model. Invest Ophthalmol Vis Sci.2010, (Epub ahead of print)
[92].Tearney GJ, Waxman S, Shishkov M, et al. Three-dimensional coronary artery microscopy by intracoronary optical frequency domain imaging. JACC Cardiovasc Imaging.2008,1(6):752-761
[93].Takarada S, Imanishi T, Liu Y, et al. Advantage of next-generation frequency-domain optical coherence tomography compared with conventional time-domain system in the assessment of coronary lesion. Catheter Cardiovasc Interv.2010,75(2):202-206
[94].Rao AK, Pratt C, Berke A, et al. Thrombolysis in Myocardial Infarction (TIMI) Trial--phase I:hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol.1988,11(1): 1-11
[95].Born GV. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature.1962,194:927-929
[96].赵明,蒋鹏,谷俊侠,等。羟乙基淀粉对血液流变学的影响。陕西医学杂志。2004,33(1)：9-11
[97].李亚茹,史婧,李娟利。冠状动脉介入治疗术后低血压与补液。实用心脑肺血管病杂志.2007,15(5)：380-381
[98].黄岚,覃军。经皮介入诊疗血管径路并发症的防治。海南医学。2002, 13(12)： 127-138
[99].Fejka M, Dixon SR, Safian RD, et al. Diagnosis, management, and clinical outcome of cardiac tamponade complicating percutaneous coronary intervention. Am J Cardiol.2002,90(11):1183-1186
[100]. Farouque HM, Tremmel JA, Raissi Shabari F, et al. Risk factors for the development of retroperitoneal hematoma after percutaneous coronary intervention in the era of glycoprotein Ⅱb/Ⅲa inhibitors and vascular closure devices. J Am Coll Cardiol.2005,45(3):363-368
[101]. Movahed MR, Balian H, Moraghebi P. Reversible severe ischemic mitral regurgitation and cardiogenic shock as a complication of percutaneous coronary intervention. J Invasive Cardiol.2005,17(2):104-107
[102]. Movahed MR, Butman SM. The pathogenesis and treatment of no-reflow occurring during percutaneous coronary intervention. Cardiovasc Revasc Med. 2008,9(1):56-61
[103]. Banfic L, Vrkic Kirhmajer M, Vojkovic M, et al. Access site complications following cardiac catheterization assessed by duplex ultrasonography. Coll Antropol.2008,32(2):385-390
[104]. Nikolsky E, Mehran R, Turcot D, et al. Impact of chronic kidney disease on prognosis of patients with diabetes mellitus treated with percutaneous coronary intervention. Am J Cardiol.2004,94(3):300-305
[105]. Valente S, Lazzeri C, Giglioli C, et al. Contrast-induced nephropathy in urgent coronary interventions. J Cardiovasc Med (Hagerstown).2006, 7(10):737-741
[1]. Mueller RL, Sanborn TA. The history of interventional cardiology:cardiac catheterization, angioplasty, and related interventions. Am Heart J.1995, 129(1):146-172
[2]. Danchin N, Juilliere Y, Kettani C, et al. Effect on early acute occlusion rate of adjunctive antithrombotic treatment with intravenously administered dipyridamole during percutaneous transluminal coronary angioplasty. Am Heart J.1994,127(3):494-498
[3].Narins CR, Holmes DR Jr, Topol EJ. A call for provisional stenting:the balloon is back! Circulation,1998,97(13):1298-1305
[4]. Serruys PW, Umans V, Heyndrickx GR, et al.403.Elective PTCA of totally occluded coronary arteries not associated with acute myocardial infarction; short-term and long-term results. Eur Heart J.1985,6(1):2-12
[5]. Cowley MJ, Dorros G, Kelsey SF, et al. Acute coronary events associated with percutaneous transluminal coronary angioplasty. Am J Cardiol.1984, 53(12):12C-16C
[6]. O'Neill WW, Weintraub R, Grines CL, et al. A prospective, placebo-controlled, randomized trial of intravenous streptokinase and angioplasty versus lone angioplasty therapy of acute myocardial infarction. Circulation.1992,86(6):1710-1717
[7]. Hirshfeld JW Jr, Schwartz JS, Jugo R, et al. Restenosis after coronary angioplasty:a multivariate statistical model to relate lesion and procedure variables to restenosis. The M-Heart Investigators. J Am Coll Cardiol.1991, 18(3):647-56
[8]. King SB III. The development of interventional cardiology. J Am Coll Cardiol.1998,31(4 suppl B):64B-88B
[9].Schatz RA, Palmaz JC, Tio FO, et al. Balloon-expandable intracoronary stents in the adult dog. Circulation.1987,76(2):450-457
[10].Sigwart U, Puel J, Mirkovitch V, et al. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med.1987, 316(12):701-706
[11].Roubin GS, Cannon AD, Agrawal SK, et al. Intracoronary stenting for acute and threatened closure complicating percutaneous transluminal coronary angioplasty. Circulation.1992,85(3):916-927
[12].Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent study group. N Engl J Med.1994, 331(8):489-495
[13].Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med. 1994,331(8):496-501
[14].Saia F, Lemos PA, Lee CH, et al. Sirolimus-eluting stent implantation in ST-elevation acute myocardial infarction:a clinical and angiographic study. Circulation.2003,108(16):1927-1929
[15].Colombo A, Drzewiecki J, Banning A, et al. Randomized study to assess the effectiveness of slow-and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation.2003,108(7):788-794
[16]. Granada JF, Kaluza GL, Raizner A. Drug-eluting stents for cardiovascular disorders. Curr Atheroscler Rep.2003,5(4):308-316
[17].Kerner A, Gruberg L, Kapeliovich M, et al. Late stent thrombosis after implantation of a sirolimus-eluting stent. Catheter Cardiovasc Interv.2003, 60(4):505-508
[18].Tsimikas S. Drug-eluting stents and late adverse clinical outcomes lessons learned, lessons awaited. J Am Coll Cardiol.2006,47(10):2112-2115
[19].Rodriguez AE, Mieres J, Fernandez-Pereira C, et al. Coronary stent thrombosis in the current drug-eluting stent era:insights from the ERACI III trial. J Am Coll Cardiol.2006,47(1):205-207
[20].Tamura A, Watanabe T, Nagase K, et al. Circadian variation in symptomatic subacute stent thrombosis after bare metal coronary stent implantation. Am J Cardiol.2006,97(2):195-197
[21]. Colombo A, Hall P, Nakamura S, et al. Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. Circulation.1995,91(6):1676-1688
[22]. Stone GW, Moses JW, Ellis SG, et al. Safety and efficacy of sirolimus-and paclitaxel-eluting coronary stents. N Engl J Med.2007,356(10):998-1008.
[23].Lau WC, Neer CJ, Watkins PB, et al. Clopidogrel nonresponders discovered during point-of-care platelet aggregation testing. J Am Coll Cardiol.2003, 41(Suppl):225A-226A
[24].McFadden EP, Stabile E, Regar E, et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet.2004, 364(94444):1519-1521
[25].Karvouni E, Korovesis S, Katritsis DG. Very late thrombosis after implantation of sirolimus eluting stent. Heart.2005,91(6):e45
[26]. Finn AV, Joner M, Nakazawa G, et al. Pathological correlates of late drug-eluting stent thrombosis:strut coverage as a marker of endothelialization. Circulation.2007,115(18):2435-2441
[27].Kotani J, Awata M, Nanto S, et al. Incomplete neointimal coverage of sirolimus-eluting stents:angioscopic findings. J Am Coll Cardiol.2006, 47(10):2108-2111
[28]. Win HK, Caldera AE, Maresh K, et al. Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. JAMA.2007, 297(18):2001-2009
[29].Fleisher LA, Beckman JA, Brown KA, et al. ACC/AHA 2007 Guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: Executive summary:A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation.2007,116(17):1971-1796
[30].Pfisterer M, Brunner-La Rocca HP, Buser PT, et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents:An observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol.2006,48(12):2584-2591
[31].Camenzind E, Steg PG, Wijns W. Stent thrombosis late after implantation of first-generation drug-eluting stents:a cause for concern. Circulation.2007, 115(11):1440-1455
[32].Daemen J, Ong AT, Stefanini GG, et al. Three-year clinical follow-up of the unrestricted use of Sirolimus-eluting stents as part of the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) Registry. Am J Cardiol.2006,98(7):895-901
[33].Williams DO, Abbott JD, Kip KE, et al. Outcomes of 6906 patients undergoing percutaneous coronary intervention in the era of drug-eluting stents:report of the DEScover Registry. Circulation.2006,114(20): 2154-2162
[34].Grines CL, Bonow RO, Casey DE Jr, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents:a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association,with representation from the American College of Physicians. Circulation.2007,115(6):813-818
[35].Ong AT, Hoye A, Aoki J, et al. Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent imp lantation. J Am Coll Cardiol.2005,45(6):947-953
[36].Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA.2005,293(17):2126-2130
[1]. Jang IK, Tearney G, Bouma B. Visualization of tissue prolapse between coronary stent struts by optical coherence tomography:comparison with intravascular ultrasound. Circulation.2001,104 (22):2754
[2]. Yabushita H, Bouma BE, Houser SL, et al. Characterization of human atherosclerosis by optical coherence tomography. Circulation.2002,106 (13): 1640-1645
[3]. Tearney GJ, Yabushita H, Houser SL, et al. Quantification of macrophage content in atherosclerotic plaques by optical coherence tomography. Circulation.2003,107:113-119
[4]. Suzuki Y, Ikeno F, Koizumi T, et al. In vivo comparison between optical coherence tomography and intravascular ultrasound for detecting small degrees of in-stent neointima after stent implantation. JACC Cardiovasc Interv.2008,1(2):168-173
[5]. Tearney GJ, Jang IK, Kang DH, et al. Porcine coronary imaging in vivo by optical coherence tomography. Acta Cardiol.2000,55(4):233-237
[6].Zimarino M, Prati F, Stabile E, et al. Optical coherence tomography accurately identifies intermediate atherosclerotic lesions--an in vivo evaluation in the rabbit carotid artery. Atherosclerosis.2007,193(1):94-101
[7]. Patwari P, Weissman NJ, Boppart SA, et al. Assessment of coronary plaque with optical coherence tomography and high-frequency ultrasound. Am J Cardiol.2000,85(5):641-644
[8]. Garcia-Garcia HM, Gonzalo N, Granada JF, et al. Diagnosis and treatment of coronary vulnerable plaques. Expert Rev Cardiovasc Ther.2008,6(2): 209-222
[9].Naghavi M, Libby P, Falk E, et al. From vulnerable plaque to vulnerable patient:a call for new definitions and risk assessment strategies:Part Ⅱ. Circulation.2003,108(15):1772-1778
[10].Tearney GJ, Yabushita H, Houser SL, et al. Quantification of macrophage content in atherosclerotic plaques by optical coherence tomography. Circulation.2003,107(1):113-119
[11].Gerckens U, Buellesfeld L, McNamara E, et al. Optical Coherence Tomography (OCT). Potential of a new high-resolution intracoronary imaging technique. Herz.2003,28(6):496-500
[12].Diaz-Sandoval LJ, Bouma BE, Tearney GJ, et al. Optical coherence tomography as a tool for percutaneous coronary interventions. Catheter Cardiovasc Interv.2005,65(4):492-496
[13].Bouma BE, Tearney GJ, Yabushita H, et al. Evaluation of intracoronary stenting by intravascular optical coherence tomography. Heart.2003,89(3): 317-320
[14].曹华明,蒋金法,邓兵,等。心肌桥的光学相干断层成像诊断及临床意义。中国介入心脏病学杂志,2009,17(6)：324-326
[15].de Jaegere P, Mudra H, Figulla H, et al. Intravascular ultrasound-guided optimized stent deployment. Immediate and 6 months clinical and angiographic results from the Multicenter Ultrasound Stenting in Coronaries Study (MUSIC Study). Eur Heart J.1998,19(8):1214-1223
[16].Colombo A, Hall P, Nakamura S, et al. Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. Circulation.1995,91(6):1676-1688
[17].Romagnoli E, Sangiorgi GM, Cosgrave J, et al. Drug eluting stenting:the case for post-dilation. J Am Coll Cardiol Intv.2008,1:22-31
[18].周圣华,卢才义,张玉霄,等。光学相干断层成像对冠状动脉支架置入后高压球囊后扩张的指导作用。临床荟萃,2010,25(5)：383-385
[19].Bouma BE, Tearney GJ, Yabushita H, et al. Evaluation of intracoronary stenting by intravascular optical coherence tomography. Heart.2003,89 (3): 317-320
[20].Ito S, Itoh M, Suzuki T. Intracoronary imaging with optical coherence tomography after cutting balloon angioplasty for in-stent restenosis. J Invasive Cardiol.2005,17(7):369-370
[21].Karantalis V, Davlouros P, Alexopoulos D. Intimal hyperplasia by optical coherence tomography after BMS and DES implantation in the same artery. Int J Cardiol.2009, (article in press)
[22].陈步星、马凤云、罗维等。光学相干断层成像评价药物洗脱支架与金属裸支架治疗后的内膜增值。中华医学杂志,2006,86(16)：1102-1106
[23].Ormiston JA, Serruys PW, Regar E, et al. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB):a prospective open-label trial. Lancet. 2008,371 (9616):899-907
[24]. Serruys PW, Ormiston JA, Onuma Y, et al. A bioabsorbable everolimus-eluting coronary stent system (ABSORB):2-year outcomes and results from multiple imaging methods. Lancet.2009,373(9667):869-870
[25].Fujii K, Masutani M, Ohyanagi M. Contribution of organized thrombus to in-stent restenosis after sirolimus-eluting stent implantation:optical coherence tomography findings. Eur Heart J.2008,29(11):1385
[26].Takano M, Xie Y, Murakami D, et al. Various optical coherence tomographic findings in restenotic lesions after sirolimus-eluting stent implantation. Int J Cardiol.2009,15,134(2):263-265
[27].Fujimoto JG, Boppart SA, Tearney GJ, et al. High resolution in vivo intra-arterial imaging with optical coherence tomography. Heart.1999,82: 128-133
[28].Gerckens U, Buellesfeld L, McNamara E, et al. Optical Coherence Tomography (OCT). Potential of a new high-resolution intracoronary imaging technique. Herz.2003,28(6):496-500
[29].颜伟,卢才义,张玉霄,等。光学相干断层成像在冠状动脉临界病变诊疗中的作用。中国介入心脏病学杂志。2007,15(3)：170
[30].Tearney GJ, Waxman S, Shishkov M, et al. Three-dimensional coronary artery microscopy by intracoronary optical frequency domain imaging. JACC Cardiovasc Imaging.2008,1(6):752-761
[31].Tearney GJ, Waxman S, Shishkov M, et al. Three-dimensional coronary artery microscopy by intracoronary optical frequency domain imaging. JACC Cardiovasc Imaging.2008,1(6):752-761
[32].Takarada S, Imanishi T, Liu Y, et al. Advantage of next-generation frequency-domain optical coherence tomography compared with conventional time-domain system in the assessment of coronary lesion. Catheter Cardiovasc Interv.2010,75(2):202-206
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |